Randomized Phase II Trial With Safety run-in Phase Evaluating Low-dose AZA, ATRA and Pioglitazone Versus Standard Dose Azacitidine in Patients ≥60 Years With AML Who Are Refractory to Standard Induction Chemotherapy

Trial Profile

Randomized Phase II Trial With Safety run-in Phase Evaluating Low-dose AZA, ATRA and Pioglitazone Versus Standard Dose Azacitidine in Patients ≥60 Years With AML Who Are Refractory to Standard Induction Chemotherapy

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2017

At a glance

  • Drugs Azacitidine (Primary) ; Pioglitazone (Primary) ; Tretinoin (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Therapeutic Use
  • Acronyms AML-ViVA
  • Most Recent Events

    • 04 Nov 2017 Status changed from recruiting to completed.
    • 01 May 2017 Status changed from not yet recruiting to recruiting.
    • 02 Nov 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top